Latest news with #RanyAburashed
Yahoo
21-05-2025
- Business
- Yahoo
Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ -- Neurogen Biomarking, the world's first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia's technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem. Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer's disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs. In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen's diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise's HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations. "Neurogen's driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey," said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. "Aranscia's proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale." Neurogen's platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer's disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care - delivered in weeks rather than the months-long wait times typically seen in traditional neurology care. "We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. "This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve." Aranscia joins Neurogen's collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns. Approximately 7 million Americans aged 65 and older were living with Alzheimer's dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer's disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer's disease by many years. About Neurogen BiomarkingNeurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer's disease – and a future with more in it. To learn more visit or follow us on LinkedIn. About Aranscia Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit Media Contacts:Neurogen Biomarking395551@ Aranscia 395551@ View original content to download multimedia: SOURCE Aranscia Sign in to access your portfolio
Associated Press
19-02-2025
- Business
- Associated Press
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease
CHICAGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking, the world's first ecosystem for memory and thinking concerns announced today that they have entered into an exclusive agreement to use Quanterix Corporation's antibody technology to measure a specific blood biomarker that serves as an early indicator of dementia and Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD). Quanterix Corporation is a company fueling scientific discovery through ultrasensitive biomarker detection. The agreement gives Neurogen Biomarking exclusive rights to commercialize Quanterix's ultrasensitive technology in direct-to-consumer testing in the United States, Europe, and pan-Asia. 'Neurogen Biomarking's agreement with Quanterix brings us one step closer to shifting the current standard of care paradigm for detection of Mild Cognitive Impairment and dementia due to Alzheimer's by giving people easier access to clinically validated blood biomarker technology,' said Dr. Rany Aburashed, Chief Executive Officer and Founder, Neurogen Biomarking. 'Our driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a responsible, scientifically and clinically controlled scalable ecosystem while also guiding them every step of the way in their brain health journey.' Neurogen Biomarking's care ecosystem includes an easy-to-use at-home blood biomarker collection test that can measure phosphorylated tau 217 (P-tau217), a specific marker for Alzheimer's disease pathology and MCI, using Quanterix's highly sensitive technology. The patient-initiated platform also provides streamlined telehealth appointments with board-certified neurologists, offering health education and a complete Brain Health Plan with actionable next steps for personalized care. 'It is Quanterix's ultrasensitive technology that made it possible to test for AD pathology in the blood. For over a decade, Quanterix has been a crucial player in this space, and we are very pleased that their cutting-edge technology is part of Neurogen Biomarking's ecosystem,' said Dr. Elisabeth Thijssen, Chief Scientific Officer, Neurogen Biomarking. 'There is a robust body of literature that shows that P-tau217 levels in blood correlate strongly with Alzheimer's disease pathology and disease progression, supporting its use as a reliable biomarker.' 1,2 Neurogen Biomarking's platform will be commercially available in early Q2 2025 for anyone eligible with memory and thinking challenges and for people concerned about symptoms that may be associated with AD. About Neurogen Biomarking An estimated 6.9 million Americans aged 65 and older were living with Alzheimer's dementia in 2024.3 Additionally, studies estimate that the prevalence of dementia and MCI is up to 22% of Americans over 65 which translates into approximately 13 million people.4 Studies reveal that MCI is underdiagnosed with average detection rates reportedly at 8% of people over 65. Patients with memory and thinking concerns often express them first to their primary care physician and then are referred to a neurologist. According to studies patients can wait from 45 to 50 months for appointment from the time they schedule an appointment with a primary care physician to seeing a neurologist.5 The current standard of care typically delays diagnosis of AD by many years which for some patients is too late for medical interventions. Neurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen Biomarking is on a mission to empower anyone with thinking, memory and neurological concerns with the tools, education, and motivation needed to access advanced, personalized care. To learn more visit LinkedIn. Media Contacts: For Neurogen Biomarking -or- Susan Reilly Reilly Connect [email protected] References Photos accompanying this announcement are available at:
